CardioSource WorldNews | Page 58
Risk Reduction Realized
75C, 63M, 63Y
5
4
3
25
50K
50C, 39M, 39Y
25K
25C, 16M, 16Y
25
25
25
80K, 80C, 70M, 70Y
5
95
5
95
5
95
5
95
25
2
75
25
25
25
25
M+Y
50
4
96
4
96
4
4
96
96
1
75K
95
5
95
5
95
5
M+Y
75
25
25
95
96
96
4
96
4
96
4
97
3
97
3
97
3
25
50
75
50
50
50
300%
50
3
97
3
97
3
97
3
97
25
75
C+Y
50
50
50
50
75
75
75
50
1
2
98
99.5
99
1
0.5
2
98
99.5
99
1
0.5
2
98
2
99
1
0.5
98
99.5
99
99.5
**Boehringer
BoehringerIngelheim
IngelheimPharmaceuticals,
Pharmaceuticals,Inc.
Inc.cannot
cannotguarantee
guaranteethe
theavailability
availabilityof
ofthe
thereversal
reversalagent.
agent.Institutions
Institutionsin
ineach
eachstate
statehave
have
purchased
purchasedthe
thereversal
reversalagent.
agent.
††
Event
Eventrates
rateswith
withPRADAXA
PRADAXAvs
vswarfarin
warfarinin
inthe
theRE-LY
RE-LY®®Trial:
Trial:135
135[2.2%]
[2.2%]vs
vs203
203[3.4%]
[3.4%]stroke/SE
stroke/SEevents,
events,HR:
HR:0.65,
0.65,95%
95%CI
CI[0.52,
[0.52,0.81],
0.81],P=0.0001;
P=0.0001;
and
and350
350[3.5%]
[3.5%]vs
vs374
374[3.6%]
[3.6%]major
majorbleeding
bleedingevents,
events,HR:
HR:0.97,
0.97,95%
95%CI
CI[0.84,
[0.84,1.12];
1.12];respectively.
respectively.22Rates
Ratesof
ofstroke/SE
stroke/SErefl
reflect
ectthe
the%
%of
ofpatients
patients
with
withan
anevent
eventat
atfifirst
rstoccurrence
occurrencein
inthe
theRE-LY
RE-LYTrial;
Trial;major
majorbleeding
bleedingevents
eventswere
werecalculated
calculatedas
as%
%per
per100
100patient-years.
patient-years.
75
Please
Pleasesee
seeImportant
ImportantSafety
SafetyInformation
Informationabout
aboutPRADAXA
PRADAXAon
onnext
nextpage.
page.
75
For
For more
more information
information and
and to
to locate
locate reversal
reversal near
near you,
you,
visit
visit PRADAXAPRO.com
PRADAXAPRO.com
C+M
50
Specifi
Specificc reversal
reversal agent
agent available
available nationwide*
nationwide*11
25
0.5
GATF/SWOP Digital
Proofing Bar
75
75
75
75
C+Y
C+M
75
50
•Superior
•Superior reduction
reduction of
of stroke/SE
stroke/SE†2†2
•Similar
•Similar rates
rates of
of major
major bleeding
bleeding†2†2
97
98
99.5
99
1
0.5
2
98
99.5
99
1
0.5
2
98
99.5
99
1
0.5
2
98
99.5
25
In
In NVAF
NVAF patients
patients vs
vs warfarin…
warfarin…
99
0.5
TM
TM